glp-1 colorectal cancer death risk study november 2025 mortality If you are taking a GLP-1 for diabetes or weight loss, a new study found it may also be lowering glp-1 colorectal cancer death risk

A phase 1 proof-of-concept clinical trial was conducted in 53 people with T2DM and translated the favorable preclinical data into clinical facts

Although there is no current evidence that gut neuropeptides or GLP-1 are implicated in the pathogenesis of IIH, these studies do highlight the therapeutic potential for GLP-1 receptor agonist in the management of IIH

Hepatic Steatosis : Recently, a sub-study of the phase 3 clinical trial SURPASS-3 showed that, among patients receiving metformin and/or SGLT2 inhibitors, the addition of tirzepatide (10 or 15 mg) as compared to insulin degludec was able to significantly reduce hepatic fat content (evaluated by magnetic resonance) after 52 weeks of treatment

Efficacy and safety of tirzepatide in type 2 diabetes and obesity management

Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission

10.3748/wjg.v30.i30.3541 79 StrowskiM